India, July 10 -- This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
Positive data readouts spanned multiple therapeutic areas, including episodic and chronic migraines, early Alzheimer's disease, Duchenne muscular dystrophy, and non-small cell lung cancer.
Let us see how the week unfolded.
Regulatory Approvals
Roche Gains CE Mark for TB Diagnostics Test
Roche (RHHBY) secured CE Mark for its Elecsys Interferon Gamma Release Assay (IGRA) TB diagnostics, offering rapid, automated detection of tuberculosis infection with results in under 24 hours. The assay demonstrated strong accuracy in global s...